Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT-101 and HT-102 in Chronic Hepatitis B
NCT07245953Phase 2Active, not recruiting
- Sponsor
- Hepatera
- Start
- Nov 2025
- Primary completion
- Feb 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Conjugated siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of HT-101, HT-102 in Chronic Hepatitis B (CHB), sponsored by Hepatera. Started Nov 2025; status: active, not recruiting.
02
Drugs
HT-101HT-102
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07245953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07245953.